PAINREFORM LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.821 USD | -10.76% |
|
+1.35% | -70.15% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.03M 169M |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -1.25B | Net income 2025 * | -17M -1.42B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.16
x | P/E ratio 2025 * |
-0.22
x | Employees | 7 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.87% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -10.76% | ||
| 1 week | +1.35% | ||
| Current month | -11.10% | ||
| 1 month | -53.62% | ||
| 3 months | -57.24% | ||
| 6 months | -65.36% | ||
| Current year | -70.15% |
1 week
0.78
0.97
1 month
0.692.55
Current year
0.692.98
1 year
0.6926.41
3 years
0.6978.40
5 years
0.6978.50
10 years
0.6978.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ilan Hadar
CEO | Chief Executive Officer | 55 | 23/20/23 |
Ehud Geller
CHM | Chairman | 77 | 01/08/01 |
Sigal Aviel
COO | Chief Operating Officer | 60 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Augustine Lawlor
BRD | Director/Board Member | 67 | 01/20/01 |
Ellen Baron
BRD | Director/Board Member | 71 | 01/20/01 |
Ehud Geller
CHM | Chairman | 77 | 01/08/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 0.821 | -10.76% | 77,988 |
| 02/24/02 | 0.92 | -2.64% | 24,562 |
| 01/24/01 | 0.9449 | +2.31% | 9,891 |
| 30/24/30 | 0.9235 | +3.59% | 12,742 |
| 29/24/29 | 0.8915 | +10.05% | 76,389 |
Delayed Quote Nasdaq, May 04, 2024 at 02:00 am IST
More quotes
PAINREFORM LTD is a Israel-based pharmaceutical Company. The Companyâs main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.821
USD
Average target price
11
USD
Spread / Average Target
+1,239.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -70.15% | 2.03M | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- PRFX Stock
